Anagenics Limited · ASX:AN1

Anagenics — Cellmid — Shareholder Meeting (October 2021)

18 slides from Anagenics's shareholder meeting presentation, Oct 22, 2021

  1. Slide 1: CEO Presentation

    Slide 1: CEO Presentation

    22 October 2021 ASX: CDY CEO PRESENTATION 1

  2. Slide 2: Forward looking statements

    Slide 2: Forward looking statements

    Forward looking statements This presentation has been prepared by Cellmid Limited ACN 111 304 119 (CDY or Company) for information purposes only. The presentation may contain forward- looking statements that are not guarantees of future performance and are subject to risks and uncertainties. Such fo

  3. Slide 3: Agenda

    Slide 3: Agenda

    Agenda ● BLC Transaction Details ● Introducing BLC Cosmetics ● Strategic Rationale of the BLC acquisition ● Combined Pro Forma PNL ● Combined Pro Forma Balance Sheet ● Growth Opportunities ● Board and Management ● FY2022 Outlook ● ESG Statement 3

  4. Slide 4: BLC Transaction Details

    Slide 4: BLC Transaction Details

    BLC Transaction Details BLC Strategic Deal Information Cosmetics Rationale ● Cellmid signed a share sale agreement with ● BLC is wholly owned by HGL Limited, a ● Scale in market with doubling of Cellmid’s HGL Limited (ASX:HNG) (HGL), to acquire diversified investment company FY2021 revenue and other

  5. Slide 5: BLC Transaction Details

    Slide 5: BLC Transaction Details

    BLC Transaction Details Board and Financial Timing Management Outcomes ● HGL will nominate a Non-Executive ● Shareholders will have the opportunity to ● Combined group revenue exceeding $13M Director to the Cellmid Board approve the issuing of based on 30 June 2021 unaudited to HGL at today’s meetin

  6. Slide 6: Introducing BLC Cosmetics

    Slide 6: Introducing BLC Cosmetics

    Introducing BLC Cosmetics FY2021 FY2021 11 900+ 8 Revenue EBITDA $7M* $500K* Premium Distribution Sales team in Up 20% on pcp Up 155% on pcp brands points including Aus and NZ DTC online 6

  7. Slide 7: BLC: Revenue Growth

    Slide 7: BLC: Revenue Growth

    BLC: Revenue Growth Revenue: FY2019 – FY2021F* Revenue growth in FY2021* was driven by new brands and increased online sales, despite lockdown impacts during the year 7

  8. Slide 8: BLC: Earnings Growth

    Slide 8: BLC: Earnings Growth

    BLC: Earnings Growth EBITDA: FY2019 – FY2021F* 8

  9. Slide 9: Strategic Rationale of BLC Acquisition

    Slide 9: Strategic Rationale of BLC Acquisition

    Strategic Rationale of BLC Acquisition • with doubling of Cellmid’s Acquisition to create an FY2021 revenue and other income of $7.3M innovative • Combined pro forma annualised revenue post merger of as of 30 June 2021, already growing through with a global organic products and channels distribution

  10. Slide 10: Combined Pro Forma Profit and Loss Statement as of 30 June 2021

    Slide 10: Combined Pro Forma Profit and Loss Statement as of 30 June 2021

    Combined Pro Forma Profit and Loss Statement as of 30 June 2021 Organic growth: CDY and BLC are expected to grow organically in FY2022 in addition to the synergies identified Synergies: Synergies are expected to result in revenue growth PLUS cost savings improving profitability Combined result: The

  11. Slide 11: Building Scale: Pro Forma Financial Position

    Slide 11: Building Scale: Pro Forma Financial Position

    Building Scale: Pro Forma Financial Position* 11

  12. Slide 12: Building Scale: Pro Forma Financial Position

    Slide 12: Building Scale: Pro Forma Financial Position

    Building Scale: Pro Forma Financial Position* 12

  13. Slide 13: Appendix 4C - Q1 FY2022

    Slide 13: Appendix 4C - Q1 FY2022

    APPENDIX 4C - Q1 FY2022 Q1 FY2022 YTD FY2022 Cash flows from operating activities $'000 $'000 Receipts from customers $2,227 $2,227 (a) research and development -$45 -$45 (b) product manufacturing and operating costs -$528 -$528 (c) advertising and marketing -$193 -$193 (d) leased assets $0 $0 (e) s

  14. Slide 14: Growth Opportunities

    Slide 14: Growth Opportunities

    Growth Opportunities Expand in China: Increase market penetration and New e-commerce platforms Increase export of heritage sales in China through recently launched progressively from brands from Japan to other Asian signed distribution agreements, June 2021, grow recurring markets, increase Japanese

  15. Slide 15: Experienced Board & Management Team

    Slide 15: Experienced Board & Management Team

    Experienced Board & Management Team Bruce Gordon | Chairman Maria Halasz | CEO and Managing Director Audit, Financial Management, Governance Strategy, Leadership, Corporate Finance, Innovation, Governance Dennis Eck | Non-Executive Director Dr Martin Cross | Non-Executive Director Strategy, Consumer

  16. Slide 16: FY2022 Outlook

    Slide 16: FY2022 Outlook

    FY2022 Outlook COVID-19: Store and salon sales are likely to : Building the Jo-Ju and continue to be affected in the first With a 1 October 2021 effective evolis brands with CDY’s distribution half of FY2022 in Australia, but settlement date CDY will benefit from three quarters of BLC sales in partn

  17. Slide 17: Driven By Environmental, Social & Governance Principles

    Slide 17: Driven By Environmental, Social & Governance Principles

    Driven By Environmental, Social & Governance Principles • We encourage diversity and respect of all sexes, races, religions and cultures amongst our employees, suppliers, customers and other stakeholders • We are committed to providing high quality, effective and ethical products to our customers •

  18. Slide 18: Thank You

    Slide 18: Thank You

    THANK YOU Maria Halasz | CEO info@cellmid.com.au +61 9221 6830 18

Source: Internet Archive copy of anagenics.com

More decks from Anagenics Limited

All 38 Anagenics decks